Liu Y, Fu Y, Wang Q, Li M, Zhou Z, Dabbagh D, et al. Proteomic profiling of HIV-1 infection of human CD4+ T cells identifies PSGL-1 as an HIV restriction factor. Nat Microbiol. 2019;4:813-825 pubmed publisher

Gentili M, Lahaye X, Nadalin F, Nader G, Puig Lombardi E, Hervé S, et al. The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. Cell Rep. 2019;26:2377-2393.e13 pubmed publisher

Lahaye X, Gentili M, Silvin A, Conrad C, Picard L, Jouve M, et al. NONO Detects the Nuclear HIV Capsid to Promote cGAS-Mediated Innate Immune Activation. Cell. 2018;175:488-501.e22 pubmed publisher

Mistry N, Sereboe L, Oakeshott P. HIV testing in pregnancy. Sex Transm Infect. 2014;90:640 pubmed publisher

Rokx C, Blonk M, Verbon A, Burger D, Rijnders B. The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2015;68:36-9 pubmed publisher

McCarthy M. HIV is detected in child thought to have been cured. BMJ. 2014;349:g4614 pubmed publisher

Chetty T, Carter R, Bland R, Newell M. HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa. Trop Med Int Health. 2014;19:852-62 pubmed publisher

Price A, Kayange M, Zaba B, Chimbwandira F, Jahn A, Chirwa Z, et al. Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study. Sex Transm Infect. 2014;90:309-14 pubmed publisher

Karlin E, Phillips E. Genotyping for severe drug hypersensitivity. Curr Allergy Asthma Rep. 2014;14:418 pubmed publisher

Ramokolo V, Lombard C, Fadnes L, Doherty T, Jackson D, Goga A, et al. HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. J Nutr. 2014;144:42-8 pubmed publisher

Owor M, Mwatha A, Donnell D, Musoke P, Mmiro F, Allen M, et al. Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. J Acquir Immune Defic Syndr. 2013;64:464-71 pubmed publisher

Cohan D, Mwesigwa J, Natureeba P, Aliba Luwedde F, Ades V, Plenty A, et al. WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity. J Acquir Immune Defic Syndr. 2013;62:e101-3 pubmed publisher

Pillay P, Ford N, Shubber Z, Ferrand R. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS ONE. 2013;8:e68995 pubmed publisher

Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André Garnier E, et al. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. J Med Virol. 2013;85:1878-82 pubmed publisher

Gupta Wright A, Wood R, Bekker L, Lawn S. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service. J Acquir Immune Defic Syndr. 2013;64:261-70 pubmed publisher

Brown E, Maldonado Y, Herron C, Chipato T, Reddy L, Moodley D, et al. HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. J Acquir Immune Defic Syndr. 2013;64:299-306 pubmed publisher

Bendle M, Bajpai S, Choudhary A, Pazare A. Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery. J Assoc Physicians India. 2012;60:39-44 pubmed

Kyaw N, Thanachartwet V, Kiertiburanakul S, Desakorn V, Chamnanchanunt S, Chierakul W, et al. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand. Southeast Asian J Trop Med Public Health. 2013;44:232-43 pubmed

Tang M, Rhee S, Bertagnolio S, Ford N, Holmes S, Sigaloff K, et al. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013;207 Suppl 2:S70-7 pubmed publisher

Otegbayo J, Kuti M, Ogunbode O, Irabor A, Adewoles I. Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy. Afr J Med Med Sci. 2012;41:417-22 pubmed

Taverne B, Desclaux A, Koita Fall M, Delaporte E, Ndoye I. Antiretroviral drugs in Africa: a public health versus a market approach. J Acquir Immune Defic Syndr. 2013;63:e74-6 pubmed publisher

Holmes D. Talk of HIV cure goes viral. Lancet Infect Dis. 2013;13:298-9 pubmed

Lowenthal E, Ellenberg J, Machine E, Sagdeo A, Boiditswe S, Steenhoff A, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA. 2013;309:1803-9 pubmed publisher

Kiage J, Heimburger D, Nyirenda C, Wellons M, Bagchi S, Chi B, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013;12:50 pubmed publisher

Audureau E, Kahn J, Besson M, Saba J, Ladner J. Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance. BMC Public Health. 2013;13:286 pubmed publisher

Hobbs C, Tanaka T, Muratova O, Van Vliet J, Borkowsky W, Williamson K, et al. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis. 2013;208:139-48 pubmed publisher

Umoren E, Obembe A, Osim E. Ulcerogenic and intestinal motility/transit stimulating actions of nevirapine in albino Wistar rats. J Physiol Biochem. 2013;69:547-57 pubmed publisher

Wang R, Weng J, Moyo S, Pain D, Barr C, Maruapula D, et al. Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection. AIDS Res Hum Retroviruses. 2013;29:901-6 pubmed publisher

Darak S, Darak T, Kulkarni S, Kulkarni V, Parchure R, Hutter I, et al. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India. AIDS Patient Care STDS. 2013;27:163-70 pubmed publisher

Ward D, Slim J. Considerations on the new nevirapine: switching patients from twice-daily to once-daily. J Int Assoc Provid AIDS Care. 2013;12:154-6 pubmed publisher

Frank M, Harms G, Kunz A, Kloft C. Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. J Clin Pharmacol. 2013;53:294-304 pubmed publisher

Maartens G. ART and tuberculosis: the final nail in nevirapine's coffin?. Lancet Infect Dis. 2013;13:278-9 pubmed publisher

Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet A, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis. 2013;13:303-12 pubmed publisher

Kumar V, Reddy B, Kumar B, Sreekanth K, Babu K. High throughput LC-MS/MS method for simultaneous determination of zidovudine, lamivudine and nevirapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;921-922:9-14 pubmed publisher

Li D, Zhan P, Liu H, Pannecouque C, Balzarini J, De Clercq E, et al. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorg Med Chem. 2013;21:2128-34 pubmed publisher

Prendergast A. Complications of long-term antiretroviral therapy in HIV-infected children. Arch Dis Child. 2013;98:245-6 pubmed publisher

Maganda B, Heudi O, Cortinovis A, Picard F, Kretz O, Minzi O. A fast and reliable reversed phase high performance liquid chromatography method for simultaneous determination of selected anti-retroviral and lumefantrine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;919-920:52-60 pubmed publisher

Decloedt E, Mwansa Kambafwile J, Van der Walt J, McIlleron H, Denti P, Smith P, et al. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. Int J Tuberc Lung Dis. 2013;17:333-5 pubmed publisher

Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka F, et al. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013;63:184-8 pubmed publisher

Sharma A, Klarskov K, Uetrecht J. Nevirapine bioactivation and covalent binding in the skin. Chem Res Toxicol. 2013;26:410-21 pubmed publisher

. Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental expos. Natl Toxicol Program Tech Rep Ser. 2013;:1-212 pubmed

. Infant feeding and transmission of human immunodeficiency virus in the United States. Pediatrics. 2013;131:391-6 pubmed publisher

Shubber Z, Calmy A, Andrieux Meyer I, Vitoria M, Renaud Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403-12 pubmed publisher

Ford N, Calmy A, Andrieux Meyer I, Hargreaves S, Mills E, Shubber Z. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS. 2013;27:1135-43 pubmed publisher

Bera E, Mia R. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. S Afr Med J. 2012;102:855-9 pubmed publisher

Bhatti L, Gladstein J. Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation. J Int Assoc Physicians AIDS Care (Chic). 2012;11:369-73 pubmed publisher

Coster L, Kumar P. Contemporary role of nevirapine in HIV treatment. AIDS Rev. 2012;14:132-44 pubmed

López Delgado J, Mendiluce R, Pinol T, Fernández X, Sanchez L, Vicente R. Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature. Ann Transplant. 2012;17:122-7 pubmed

Heil E, Corbett A. Guidelines for the use of extended-release nevirapine in HIV-infected patients. Expert Opin Pharmacother. 2011;12:2713-8 pubmed publisher

Muret P, Piédoux S, Solas C, Quaranta S. [Evidence-based therapeutic drug monitoring for nevirapine]. Therapie. 2011;66:187-95 pubmed publisher

Parienti J, Peytavin G. Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. Expert Opin Drug Metab Toxicol. 2011;7:495-503 pubmed publisher

Mbuagbaw L, Irlam J, Spaulding A, Rutherford G, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;:CD004246 pubmed publisher

Parienti J, Verdon R. [Nevirapine and cardiovascular risk]. Med Mal Infect. 2010;40:499-505 pubmed publisher

Popovic M, Shenton J, Chen J, Baban A, Tharmanathan T, Mannargudi B, et al. Nevirapine hypersensitivity. Handb Exp Pharmacol. 2010;:437-51 pubmed publisher

Kazennova E. [Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission from HIV-infected mother to infant]. Vopr Virusol. 2009;54:45-8 pubmed

Han J, Jiang Y. [Prevention of mother-to-child transmission with single dose nevirapine and human immunodeficiency virus drug resistance]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:730-3 pubmed

Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Med. 2008;9:747-56 pubmed publisher

Medrano J, Barreiro P, Tuma P, Vispo E, Labarga P, Blanco F, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev. 2008;10:110-5 pubmed

Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. Lancet Infect Dis. 2007;7:733-8 pubmed

McConnell M, Stringer J, Kourtis A, Weidle P, Eshleman S. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?. Am J Obstet Gynecol. 2007;197:S56-63 pubmed